These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2959472)

  • 41. Outcomes of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection.
    Murray MP; Laurenson IF; Hill AT
    Clin Infect Dis; 2008 Jul; 47(2):222-4. PubMed ID: 18532890
    [TBL] [Abstract][Full Text] [Related]  

  • 42. On the possibility of cross-resistance between rifampicin and clofazimine in mycobacteria--a laboratory study.
    Urbanczik R
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Aug; 260(1):113-6. PubMed ID: 3933210
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antimycobacterial activity of ionic fullerene derivatives.
    Bosi S; Da Ros T; Castellano S; Banfi E; Prato M
    Bioorg Med Chem Lett; 2000 May; 10(10):1043-5. PubMed ID: 10843212
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activity of 4,5-dihydro-1H-pyrazoles against Mycobacterium tuberculosis and nontuberculous mycobacteria.
    Ramos DF; Fiss G; Frizzo CP; Martins MA; Bonacorso HG; Zanatta N; Almeida da Silva PE
    Int J Antimicrob Agents; 2014 May; 43(5):481-3. PubMed ID: 24713182
    [No Abstract]   [Full Text] [Related]  

  • 45. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria.
    Young LS; Berlin OG; Inderlied CB
    Am J Med; 1987 Apr; 82(4A):23-6. PubMed ID: 3107379
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro susceptibility of Mycobacterium fortuitum, Mycobacterium chelonae and Mycobacterium avium against some quinolones.
    Casal M; Rodriguez F; Villalba R; Benavente MC; Gonzalez AI
    Chemioterapia; 1987 Dec; 6(6):431-3. PubMed ID: 3481302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro activity of ciprofloxacin and ofloxacin against the Mycobacterium avium-intracellulare complex.
    Johnson SM; Roberts GD
    Diagn Microbiol Infect Dis; 1987 May; 7(1):89-91. PubMed ID: 3121243
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of antimicrobial agents against mycobacteria.
    Casal M; Rodríguez F; Gutierrez J; Ruíz P; Villalba R
    Drugs Exp Clin Res; 1988; 14(12):741-5. PubMed ID: 3150951
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin.
    Vacher S; Pellegrin JL; Leblanc F; Fourche J; Maugein J
    J Antimicrob Chemother; 1999 Nov; 44(5):647-52. PubMed ID: 10552981
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antimycobacterial evaluation of germacranolides.
    Fischer NH; Lu T; Cantrell CL; Castañeda-Acosta J; Quijano L; Franzblau SG
    Phytochemistry; 1998 Sep; 49(2):559-64. PubMed ID: 9747541
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and antimycobacterial activity of some N1-[1-[3-aryl-1-(pyridin-2-, 3-, or 4-yl)-3-oxo]propyl]-2- pyridinecarboxamidrazones.
    Mamolo MG; Falagiani V; Vio L; Banfi E
    Farmaco; 1999; 54(11-12):761-7. PubMed ID: 10668176
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative activity of azithromycin against clinical isolates of mycobacteria.
    Watt B; Rayner A; Harris G
    J Antimicrob Chemother; 1996 Sep; 38(3):539-42. PubMed ID: 8889727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro antimycobacterial activity of a new antibacterial substance DL-8280--differentiation between some species of mycobacteria and related organisms by the DL-8280 susceptibility test.
    Tsukamura M
    Microbiol Immunol; 1983; 27(12):1129-32. PubMed ID: 6587177
    [No Abstract]   [Full Text] [Related]  

  • 54. In vitro susceptibility of human and environmental isolates of Mycobacterium avium, M. intracellulare, and M. scrofulaceum to heavy-metal salts and oxyanions.
    Falkinham JO; George KL; Parker BC; Gruft H
    Antimicrob Agents Chemother; 1984 Jan; 25(1):137-9. PubMed ID: 6230989
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to cefmetazole.
    Casal MJ; Rodriguez FC; Benavente MC
    Antimicrob Agents Chemother; 1985 Feb; 27(2):282-3. PubMed ID: 3857020
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug susceptibility testing of nontuberculous mycobacteria.
    van Ingen J; Kuijper EJ
    Future Microbiol; 2014; 9(9):1095-110. PubMed ID: 25340838
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Brown-Elliott BA; Rubio A; Wallace RJ
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126964
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In-vitro inhibition of mycobacteria by viridans streptococci.
    Allen BW
    J Med Microbiol; 1985 Apr; 19(2):227-35. PubMed ID: 3920400
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Comparison of in vitro antimycobacterial activities of ansamycin and rifampicin].
    Tsukamura M; Mizuno S; Toyama H; Ichiyama S
    Kekkaku; 1986 Oct; 61(10):497-503. PubMed ID: 3100853
    [No Abstract]   [Full Text] [Related]  

  • 60. Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria.
    Banks J; Jenkins PA
    Thorax; 1987 Nov; 42(11):838-42. PubMed ID: 3424264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.